Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U01TR002743 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Center for Advancing Translational Sciences (NCATS) | NIH |
Not provided
Not provided
Not provided
Not provided
Researchers are trying to better understand how people who are prescribed opioids for short-term use, go on to receive this type of medication on a longer-term basis.
Identify incident cases of UPOU and prospectively assess their characteristics in comparison to new opioid users who do not progress to UPOU. At each site, opioid-naïve adults who receive opioid prescriptions will be enrolled. Opioid prescriptions (both written and filled) and self-reported opioid use will be followed, and those subjects progressing to UPOU will be identified in real time. Matched samples of patients who do and do not develop UPOU will be recruited for assessment of framework elements related to patient characteristics,including biochemical confirmation of opioid use, pain-related measures (including psychological variables), and medical and social histories. Using the information gathered in Aim 1, structural equation modeling will be utilized to evaluate the associations UPOU and the patient domain.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Assess the rate of long-term opioid use | At month 6 following the receipt of the initial opioid prescription, the status of opioid use will be assessed to determine the rate of converting to long-term use. | Six months |
| Measure | Description | Time Frame |
|---|---|---|
| Assess patient factors associated with development of long-term opioid use | Patient factors potentially associated development of long-term opioid use will be assessed including depressive symptoms as measured using the Center for Epidemiological Studies-Depression Scale. Scores on the scale range from 0 to 60 where higher scores indicated greater levels of depression. A cut-off score of 27 or greater indicates clinically significant levels of depression. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Any individual that receives an opioid prescription.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| W. Michael Hooten, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41800757 | Derived | Hooten WM, Erickson DJ, Chawarski M, Scholz NA, Waljee JF, Brummett CM, Jeffery MM. Unintended prolonged opioid use: a prospective case-control study. Pain. 2026 Jun 1;167(6):e180-e190. doi: 10.1097/j.pain.0000000000003945. Epub 2026 Mar 4. | |
| 39992690 | Derived | Hooten WM, Erickson DJ, Chawarski M, Scholz NA, Waljee JF, Brummett CM, Jeffery MM. Unintended Prolonged Opioid Use: Protocol for a Case-Controlled Trial. JMIR Res Protoc. 2025 Mar 24;14:e72032. doi: 10.2196/72032. |
| Label | URL |
|---|---|
| Mayo Clinic Clinical Trials | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Six months |